多重系統退化症症市場－全球產業規模、佔有率、趨勢、機會及預測（依診斷、年齡、最終用戶、地區及競爭格局分類，2021-2031年）

全球多重系統退化症症市場預計將從 2025 年的 1.5439 億美元成長到 2031 年的 1.8553 億美元，複合年成長率為 3.11%。

該市場涵蓋了針對這種罕見進行性神經退化性疾病的症狀治療藥物以及新興的緩解疾病藥物的研發和商業化。推動這一成長的主要因素是診斷通訊協定的改進和臨床意識的提高，這縮短了從症狀出現到準確診斷的時間。為了佐證這項檢測能力提升的趨勢，多重系統退化症症信託基金報告稱，2024年本地註冊患者人數較2020年成長了38%，顯示需要特殊護理的患者群體顯著擴大。

儘管取得了這些進展，但由於診斷上的模糊性，市場仍面臨著巨大的障礙，因為早期多重系統退化症症（MSA）的症狀通常與帕金森氏症相似。這種臨床重疊常常導致誤診，顯著增加了臨床試驗的患者招募難度，並提高了臨床實驗藥物失敗的風險。因此，這些診斷難題延緩了新治療方法的上市進程，並凸顯了持續尋找更明確的診斷標記物以區分MSA與相關疾病的迫切需求。

市場促進因素

一系列強大的新型疾病修正治療正在推動全球多重系統退化症症 (MSA) 市場的發展，使該行業的關注點從症狀治療轉向潛在的根治性干預。這一發展勢頭體現在針對 α-突觸核蛋白病理（疾病進展的核心促進因素）的後期臨床試驗數量的增加。例如，2025 年 7 月，Alterity Therapeutics 公佈了一項 II 期研究的主要數據，結果顯示其主要候選藥物 ATH434 與歷史對照組相比，可抑制疾病進展約 50%。為了展示研究規模的擴大，《實用神經病學》雜誌於 2025 年 2 月報道，一項新的 Amrenetag III 期臨床試驗已啟動，計劃在國際中心招募 300 多名受試者。

同時，有利的監管激勵措施和孤兒藥認定正在降低開發罕見神經退化性疾病治療藥物相關的財務風險，從而加速市場成長。監管機構積極鼓勵創新，加速核准流程，這對於快速將有前景的治療方法帶給急需治療的患者至關重要。一個顯著的例子是，靈北製藥於2025年2月宣布，美國食品藥物管理局（FDA）授予Amrenetag簡審類，此前該藥物的二期臨床試驗數據顯示，在特定患者亞群中，其臨床進展延遲了37%。這些里程碑不僅加快了研發進程，也向投資者證明了商業性可行性，並確保了複雜藥物計畫的永續資金籌措。

市場挑戰

多重系統退化症症 (MSA) 的診斷模糊性嚴重阻礙了其在全球市場的擴張。由於 MSA 的早期症狀，例如運動僵硬和自主神經功能障礙，與帕金森氏症非常相似，患者常常被誤診，或需要很長時間才能確診。這種臨床上的不確定性直接阻礙了藥物開發平臺，進而影響了市場發展。準確識別患者是臨床試驗成功的關鍵。如果潛在候選患者被錯誤識別，或診斷過晚而無法符合入組標準，則會導致患者招募效率低下，試驗失敗的風險增加，最終導致對新型療法的投資減少。

目前的臨床環境充分體現了此障礙的嚴重性：根據國際帕金森氏症和運動障礙協會的數據，2024年的臨床數據顯示，早期多重系統退化症症的誤診率高達21%至38%。如此高的誤診率使得研究目的的患者分層變得複雜，導致新藥檢驗和有效治療方法商業性化應用於該患者群體的時間被延誤。

市場趨勢

新型神經影像學和體液生物標記技術的應用正在從根本上重塑市場格局，將診斷通訊協定從主觀的臨床觀察轉向嚴格的生物學檢驗。這一趨勢旨在解決該領域最棘手的難題：透過引入種子擴增檢測等先進工具，區分多重系統退化症與類似的突觸病變。這些技術正迅速從研究階段走向商業應用，從而實現更早期的患者分層，並降低因誤診而導致的試驗失敗率。為了展示這種整合，梅約診所研究所於2025年3月發布新聞稿，宣布與Amprion公司合作推出SAAmplify-αSYN檢測。此檢測是一種體液生物標記檢測，能夠在明顯的臨床症狀出現前數年檢測到退化性α-突觸核蛋白病變。

與之並行的趨勢是姿態性低血壓(NOH) 臨床試驗的擴展。這一趨勢除了關注治療方法外，還著重研究該疾病特有的嚴重自主神經功能障礙。緩解疾病療法旨在治療潛在的神經退化，而這一趨勢則優先考慮即時改善飽受血壓波動折磨的患者的生活品質。鑑於持久緩解症狀的緊迫性，製藥公司正積極推動該適應症的後期臨床試驗。例如，Theravance Biopharma 在 2025 年 8 月的企業資料更新中宣布了其 III 期 CYPRESS 試驗的進展，透露已完成安培洛西汀（一種用於治療神經源性體位性低血壓症狀的藥物）在美國約 4 萬名患者的入組。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球多重系統退化症症市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 透過診斷（磁振造影（MRI）、正子斷層掃描（PET）、單光子發射電腦斷層掃描（SPECT）、傾斜試驗、其他）
  • 依年齡（兒童、成人、老年人）
  • 依最終使用者（醫院、門診手術中心、其他）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

6. 北美多重系統退化症症市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲多重系統退化症症市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區多重系統退化症症市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲多重系統退化症症市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

10. 南美多重系統退化症症市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球多重系統退化症症市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Biohaven Ltd.
• Theravance Biopharma
• Sumitomo Dainippon Pharma Co., Ltd.
• Alterity Therapeutics
• AstraZeneca plc.
• Biogen
• Merck & Co., Inc.
• Neuropore Therapies, Inc.
• WaveBreak Therapeutics
• Newron Pharmaceuticals SPA

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Multiple System Atrophy Market is projected to expand from USD 154.39 Million in 2025 to USD 185.53 Million by 2031, reflecting a Compound Annual Growth Rate of 3.11%. This market involves the development and commercialization of both symptomatic treatments and emerging disease-modifying agents aimed at this rare, progressive neurodegenerative disorder. A key factor driving this growth is the refinement of diagnostic protocols combined with heightened clinical awareness, which together are reducing the delay between symptom onset and accurate identification. Supporting this trend of improved detection, the Multiple System Atrophy Trust reported in 2024 that community registrations had increased by 38% since 2020, indicating a significant expansion in the recognized patient population requiring specialized care.

Despite these advances, the market faces a substantial obstacle due to diagnostic ambiguity, as early-stage MSA symptoms often resemble those of Parkinson's disease. This clinical overlap frequently results in misdiagnosis, which severely complicates patient recruitment for clinical trials and elevates the risk of failure for investigational drugs. Consequently, these diagnostic challenges impede the timely introduction of novel therapies to the market, highlighting the persistent need for more distinct diagnostic markers to distinguish MSA from related conditions.

Market Driver

A robust pipeline of novel disease-modifying therapies serves as a primary catalyst for the Global Multiple System Atrophy Market, shifting the industry focus from symptomatic management to potential curative interventions. This momentum is defined by an increasing number of late-stage clinical trials targeting alpha-synuclein pathology, which is central to the disease's progression. For example, Alterity Therapeutics announced in July 2025 that topline data from a Phase 2 trial showed their lead candidate, ATH434, reduced disease progression by approximately 50% compared to historical controls. Highlighting the expanding scale of research, Practical Neurology reported in February 2025 that a new Phase 3 clinical trial was initiated for amlenetug, aiming to enroll over 300 participants across international sites.

Simultaneously, favorable regulatory incentives and Orphan Drug Designations are accelerating market growth by mitigating the financial risks associated with developing treatments for rare neurodegenerative disorders. Regulatory agencies are actively encouraging innovation through expedited review pathways, which are essential for rapidly bringing promising therapies to patients with high unmet needs. A notable example occurred in February 2025, when Lundbeck announced that the U.S. FDA granted Fast Track Designation to amlenetug after Phase 2 data indicated a 37% slower rate of clinical progression in a specific patient subgroup. These milestones not only expedite development timelines but also signal commercial viability to investors, ensuring sustained funding for complex drug programs.

Market Challenge

The diagnostic ambiguity associated with Multiple System Atrophy (MSA) stands as a critical impediment to the global market's expansion. Because early-stage symptoms of MSA, such as motor rigidity and autonomic dysfunction, closely mimic those of Parkinson's disease, patients are frequently misdiagnosed or endure long delays before receiving an accurate confirmation. This clinical uncertainty directly hampers the market by disrupting the drug development pipeline; precise patient identification is essential for the success of clinical trials. When potential candidates are misidentified or diagnosed too late to meet inclusion criteria, recruitment becomes inefficient, and the risk of trial failure increases, which subsequently discourages investment in new therapeutic agents.

The magnitude of this obstacle is significant within the current clinical landscape. According to the International Parkinson and Movement Disorder Society, clinical data from 2024 indicated that misdiagnosis rates for early-stage Multiple System Atrophy ranged between 21% and 38%. This substantial margin of error complicates patient stratification for research purposes, thereby slowing the validation of emerging drugs and delaying the commercial introduction of effective treatments to the patient population.

Market Trends

The adoption of novel neuroimaging and fluid biomarker technologies is fundamentally reshaping the market by transitioning diagnostic protocols from subjective clinical observation to precise biological validation. This trend addresses the sector's most persistent challenge-distinguishing Multiple System Atrophy from similar synucleinopathies-by deploying advanced tools such as seed amplification assays. These technologies are rapidly moving from research settings to commercial availability, enabling earlier patient stratification and reducing the costly failure rates associated with misdiagnosed trial participants. Validating this integration, Mayo Clinic Laboratories announced in a March 2025 press release regarding a partnership with Amprion the launch of the SAAmplify-ɑSYN test, a fluid biomarker assay capable of detecting misfolded alpha-synuclein pathology years before the onset of overt clinical symptoms.

A parallel trend involves the expansion of clinical trials for Neurogenic Orthostatic Hypotension, focusing on the severe autonomic dysfunction that characterizes the disease alongside curative efforts. While disease-modifying agents target underlying neurodegeneration, this trend prioritizes immediate quality-of-life improvements for patients suffering from debilitating blood pressure volatility. Pharmaceutical developers are aggressively advancing late-stage studies for this indication, recognizing the urgent need for durable symptomatic relief. For instance, in an August 2025 corporate update regarding the Phase 3 CYPRESS trial, Theravance Biopharma announced the completion of patient enrollment for ampreloxetine, a therapy designed to treat symptomatic neurogenic orthostatic hypotension in a targeted population of approximately 40,000 U.S. patients.

Key Market Players

• Biohaven Ltd.
• Theravance Biopharma
• Sumitomo Dainippon Pharma Co., Ltd.
• Alterity Therapeutics
• AstraZeneca plc.
• Biogen
• Merck & Co., Inc.
• Neuropore Therapies, Inc.
• WaveBreak Therapeutics
• Newron Pharmaceuticals SPA

Report Scope

In this report, the Global Multiple System Atrophy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Multiple System Atrophy Market, By Diagnosis

• Magnetic Resonance Imaging (MRI)
• Positron Emission Tomography (PET)
• Single Photon Emission Computed Tomography (SPECT)
• Tilt Table Test
• Others

Multiple System Atrophy Market, By Age

• Pediatric
• Adults
• Geriatric

Multiple System Atrophy Market, By End User

• Hospitals
• Ambulatory Surgical Centers
• Others

Multiple System Atrophy Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Multiple System Atrophy Market.

Available Customizations:

Global Multiple System Atrophy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Multiple System Atrophy Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Diagnosis (Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), Tilt Table Test, Others)
  • 5.2.2. By Age (Pediatric, Adults, Geriatric)
  • 5.2.3. By End User (Hospitals, Ambulatory Surgical Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Multiple System Atrophy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Diagnosis
  • 6.2.2. By Age
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Multiple System Atrophy Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Diagnosis
      • 6.3.1.2.2. By Age
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Multiple System Atrophy Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Diagnosis
      • 6.3.2.2.2. By Age
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Multiple System Atrophy Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Diagnosis
      • 6.3.3.2.2. By Age
      • 6.3.3.2.3. By End User

7. Europe Multiple System Atrophy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Diagnosis
  • 7.2.2. By Age
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Multiple System Atrophy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Diagnosis
      • 7.3.1.2.2. By Age
      • 7.3.1.2.3. By End User
  • 7.3.2. France Multiple System Atrophy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Diagnosis
      • 7.3.2.2.2. By Age
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Multiple System Atrophy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Diagnosis
      • 7.3.3.2.2. By Age
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Multiple System Atrophy Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Diagnosis
      • 7.3.4.2.2. By Age
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Multiple System Atrophy Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Diagnosis
      • 7.3.5.2.2. By Age
      • 7.3.5.2.3. By End User

8. Asia Pacific Multiple System Atrophy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Diagnosis
  • 8.2.2. By Age
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Multiple System Atrophy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Diagnosis
      • 8.3.1.2.2. By Age
      • 8.3.1.2.3. By End User
  • 8.3.2. India Multiple System Atrophy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Diagnosis
      • 8.3.2.2.2. By Age
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Multiple System Atrophy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Diagnosis
      • 8.3.3.2.2. By Age
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Multiple System Atrophy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Diagnosis
      • 8.3.4.2.2. By Age
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Multiple System Atrophy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Diagnosis
      • 8.3.5.2.2. By Age
      • 8.3.5.2.3. By End User

9. Middle East & Africa Multiple System Atrophy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Diagnosis
  • 9.2.2. By Age
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Multiple System Atrophy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Diagnosis
      • 9.3.1.2.2. By Age
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Multiple System Atrophy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Diagnosis
      • 9.3.2.2.2. By Age
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Multiple System Atrophy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Diagnosis
      • 9.3.3.2.2. By Age
      • 9.3.3.2.3. By End User

10. South America Multiple System Atrophy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Diagnosis
  • 10.2.2. By Age
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Multiple System Atrophy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Diagnosis
      • 10.3.1.2.2. By Age
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Multiple System Atrophy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Diagnosis
      • 10.3.2.2.2. By Age
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Multiple System Atrophy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Diagnosis
      • 10.3.3.2.2. By Age
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Multiple System Atrophy Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Biohaven Ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Theravance Biopharma
• 15.3. Sumitomo Dainippon Pharma Co., Ltd.
• 15.4. Alterity Therapeutics
• 15.5. AstraZeneca plc.
• 15.6. Biogen
• 15.7. Merck & Co., Inc.
• 15.8. Neuropore Therapies, Inc.
• 15.9. WaveBreak Therapeutics
• 15.10. Newron Pharmaceuticals SPA

16. Strategic Recommendations

17. About Us & Disclaimer